Structure Therapeutics (GPCR) Cash & Equivalents (2022 - 2026)

Structure Therapeutics' Cash & Equivalents history runs 5 years deep, the most recent figure standing at $1.5 billion for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 73.6% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $1.5 billion (up 73.6% YoY), while the FY2025 annual figure was $799.6 million, down 8.65% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $1.5 billion, up from $799.6 million in the prior quarter.
• The five-year high for Cash & Equivalents was $1.5 billion in Q1 2026, with the low at $26.1 million in Q4 2022.
• The 5-year median for Cash & Equivalents is $212.5 million (2023), against an average of $447.8 million.
• Peak annual rise in Cash & Equivalents reached 755.45% in 2025, while the deepest fall reached 61.47% in 2025.
• Structure Therapeutics' Cash & Equivalents stood at $26.1 million in 2022, then jumped by 397.46% to $129.8 million in 2023, then surged by 574.41% to $875.3 million in 2024, then dropped by 8.65% to $799.6 million in 2025, then surged by 81.7% to $1.5 billion in 2026.
• Business Quant data shows GPCR's Cash & Equivalents at $1.5 billion in Q1 2026, $799.6 million in Q4 2025, and $799.0 million in Q3 2025.